Buy Vigora Online

Vigora Information

Introduction

Vigora is a oral tablet containing the active compound sildenafil, indicated for the treatment of erectile dysfunction (ED) in adult men. In the United Kingdom it is classified within the therapeutic group “Erectile Dysfunction, Men’s Health.” Sildenafil also has a recognised role in the management of pulmonary arterial hypertension, although the dosage and formulation differ from those used for ED. The medication is manufactured by several licensed producers and is distributed globally under various generic trade names.

What is Vigora?

Vigora is a sildenafil‑based tablet formulated to improve erectile function by enhancing the natural blood flow response to sexual stimulation. The product is marketed as a generic alternative to brand‑name sildenafil preparations such as Viagra® and Revatio®. It is manufactured by GMP‑certified facilities that adhere to European Medicines Agency (EMA) standards, ensuring consistent potency and purity. Vigora is supplied in 25 mg, 50 mg and 100 mg tablets, each tablet containing only the stated amount of sildenafil citrate as the sole active ingredient.

How Vigora Works

Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5). In the corpus cavernosum of the penis, sexual arousal triggers the release of nitric oxide, which stimulates cyclic guanosine monophosphate (cGMP). cGMP relaxes smooth muscle and allows blood to fill the erectile tissue. PDE5 normally degrades cGMP, limiting the erection. By blocking PDE5, Vigora prolongs the cGMP signal, resulting in a sustained inflow of blood and an erection that is sufficient for sexual activity. The drug is absorbed rapidly after oral ingestion, reaching peak plasma concentrations within 30–120 minutes. Its half‑life averages 3–5 hours, providing therapeutic effect for up to four to six hours. Food, especially high‑fat meals, can delay absorption but does not markedly reduce overall effectiveness.

Treated with Vigora

• Erectile Dysfunction (ED): The primary indication. ED affects an estimated 1.5 million men in the UK, with prevalence increasing with age. Sildenafil improves erection quality in the majority of patients when taken as needed.
• Pulmonary Arterial Hypertension (PAH) – off‑label/alternative dosing: In specialist settings, sildenafil is used at lower, divided doses to lower pulmonary vascular resistance, though this use requires specialist supervision.

Vigora’s efficacy in these conditions is supported by large, multi‑national clinical trials, including the pivotal Phase III studies that demonstrated significant improvement in the International Index of Erectile Function (IIEF) scores compared with placebo.

Suitable Candidates for Vigora Treatment

• Men aged 18 years and older with a confirmed diagnosis of erectile dysfunction.
• Individuals with stable cardiovascular status who are not taking nitrates or other contraindicated medications.
• Patients who have tried lifestyle optimisation (e.g., smoking cessation, weight loss) without sufficient resolution of symptoms.
• Those preferring a discreet, oral on‑demand therapy rather than daily hormonal or injectable options.

Vigora is not appropriate for men who:

• Are using any nitrate medication (e.g., nitroglycerin, isosorbide dinitrate).
• Have uncontrolled hypertension, recent myocardial infarction, or severe heart failure.
• Suffer from congenital retinal disorders such as retinitis pigmentosa.
• Have severe hepatic or renal impairment without dosage adjustment.

Risks, Side Effects, and Interactions

Common

• Headache
• Facial flushing
• Dyspepsia (indigestion)
• Nasal congestion
• Visual disturbances (blurred vision, colour tinge)

These events are usually mild to moderate, transient, and resolve without medical intervention.

Rare

• Back pain or myalgia (muscle aches)
• Priapism (prolonged erection lasting > 4 hours)
• Dizziness or light‑headedness
• Auditory changes (tinnitus, hearing loss)

Patients experiencing rare side effects should seek medical advice promptly, especially for priapism, which requires emergency treatment to prevent permanent tissue damage.

Serious

• Severe hypotension, particularly when combined with nitrates or potent antihypertensives
• Acute cardiovascular events (myocardial infarction, stroke) in high‑risk individuals
• Sudden vision loss (non‑arteritic anterior ischemic optic neuropathy – NAION)
• Anaphylactic reaction (extremely uncommon)

Any serious adverse event warrants immediate emergency care.

Clinically Relevant Drug–Drug Interactions

• Nitrates (e.g., glyceryl trinitrate, isosorbide mononitrate): Co‑administration can cause dangerous drops in blood pressure.
• Alpha‑blockers (e.g., tamsulosin, alfuzosin): May lead to additive hypotensive effects; dose spacing is advised.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, protease inhibitors): Increase sildenafil plasma levels, potentially heightening side‑effect risk; dose reduction may be needed.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): Decrease drug exposure, possibly reducing efficacy.
• Other PDE5 inhibitors: Concurrent use is contraindicated due to additive vasodilatory effect.

Patients should disclose all current medications, including over‑the‑counter products and herbal supplements, to their healthcare provider before starting Vigora.

Practical Use: Dosing, Missed Dose, Overdose

• Initial dose: 50 mg taken as a single tablet, approximately 30–60 minutes before anticipated sexual activity.
• Dose adjustment: Depending on efficacy and tolerability, the dose may be decreased to